CCRM and Affigen Partner to Develop Personalized Therapeutics for B-Cell Lymphoma, Leukemia
News
CCRM, a Canadian nonprofit that develops regenerative medicine technologies, and Affigen will collaborate on the development and commercialization of a closed platform that produces targeted therapies personalized for a patient’s ... Read more